Beijing Tiantan Biological Products Co Ltd (Tiantan Biological Products) (stock code: 600161.SH) went public on the Shanghai Stock Exchange in 1998. It is a third-tier subsidiary of China National Pharmaceutical Group Co Ltd (Sinopharm), with China National Biotec Group Co Ltd (CNBG) as its controlling shareholder. After two major asset reorganizations in 2010 and 2017, Tiantan Biological Products became the only specialized blood products company under CNBG. It manages six blood product manufacturing enterprises, including Chengdu Rongsheng Pharmaceutical Co Ltd, Lanzhou Lansheng Blood Products Co Ltd, Shanghai RAAS Blood Products Co Ltd, Sinopharm Group Wuhan Blood Products Co Ltd, Sinopharm Group Guizhou Blood Products Co Ltd, and Xi'an Huitian Blood Products Co Ltd. The company operates 85 plasma collection stations (including 60 operational stations and 25 planned stations) in 15 provinces and autonomous regions across China.

Tiantan Biological Products produces three major categories of products: human albumin, human immunoglobulin and human coagulation factors, with a total of 14 varieties and 72 production licenses. The company occupies a leading position in terms of scale in China and has comprehensive advantages in terms of quality, scale and brand.

As a national leading company in blood products R&D and production, Tiantan Biological Products has provided strategic reserves of blood products for major national events such as the Beijing Winter and Summer Olympics, as well as in response to major disasters like the Wenchuan Earthquake in 2008 and the outbreak of SARS in 2003. It has been committed to safeguarding public health. Since the outbreak of the COVID-19 pandemic, Tiantan Biological Products has fully dedicated its efforts to epidemic prevention and control. Following the principle of building a community with a shared future for mankind, it has participated in foreign medical aid, injecting strong impetus into global fight against the pandemic.